Forward P/S Multiple: Tenon Medical (TNON)
Slow adoption of implants by surgeons and insurance risks are constraining growth rates. This chart from the GURU.Markets terminal illustrates the expected revenue multiple, where the parameter has stabilized at 0.70. Alliances with clinics to implement the Catamaran system and the acquisition of patents are creating synergy. A steady cash flow from scheduled joint fixation procedures is strengthening the current financial health of Tenon Medical, Inc. (TNON).
Summary analytical data breakdowns for Tenon Medical, Inc. (TNON)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Tenon Medical, Inc.|TNON - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital tenonmed.com|TNON - Company Aggregate Debts|Debt to Book Capitalization Ratio Tenon Medical, Inc.|TNON - Company Long-Term Debt|Company Current Liabilities Tenon Medical|Quick Ratio tenonmed.com
- financial results and valuation multiples details:
TNON - Company Net Income|Expected Profit Tenon Medical, Inc.|TNON - Market Cap to Net Income Ratio|Projected Price to Earnings Tenon Medical Inc|TNON - PEG Multiple|EV/EBITDA Multiple Tenon Medical, Inc|TNON - Operating income before deduction of amortization|Earnings per share for the last twelve months Tenon Medical|TNON - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months tenonmed.com|TNON - Net earnings per share growth this year|Earnings growth forecast for next year Tenon Medical, Inc.
- sales and revenue indicators:
Fundamental company analysis:TNON (Tenon Medical, Inc)
Tenon Medical, Inc. (TNON) specialization in high-tech systems for treating sacroiliac joint pathologies creates a stable foundation within the orthopedic niche. By analyzing the forward P/S multiple, an investor assesses the ratio of current market capitalization to projected revenue, which allows for determining the extent of overpayment for future earnings and eliminates the risk of purchasing an overheated asset amid inflationary pressures.
Who Tenon Medical, Inc. competes with
Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Inc) - Forward Price-to-Revenue Multiple|IRADIMED CORPORATION - Forward Price to Sales|EMBC (Embecta Health) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tandem Diabetes Care Inc TNDM|Price-to-Projected Revenue Ratio AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Projected Price to Revenue|Orthofix Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio bioventus.com (BVS)|OrthoPediatrics Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed Medical)|Price-to-Projected Revenue Ratio rxsight.com|Forward Price-to-Revenue Multiple ClearPoint Neuro, Inc. (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences, Inc. SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD, Inc. - Price to Expected Revenue Ratio|zhjmedical.com (ZJYL) - Price-to-Projected Revenue Ratio|VANI (Vivani Medical Inc) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple XTNT|Market Cap to Future Revenue Ratio NeuroOne Medical Technologies NMTC|Forward P/S Multiple MODD|Forward Price-to-Revenue Multiple myomo.com MYO|Price-to-Projected Revenue Ratio Envoy Medical Inc COCH|Vivos Therapeutics Inc. (VVOS) - Market Cap to Future Revenue Ratio|envveno.com - Forward P/S Multiple|SINT (Sintx Technologies Inc) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple
